Mortality analysis in cases of COVID-19 during the second wave at a tertiary care center in western India

India witnessed a devastating second surge of COVID-19 cases from March 2021. Evidence strongly advocates its association with the patients’ age, gender, pre-existing comorbidity, vaccination status, and Remdesivir administration during the treatment of the disease. The objective of this study is to evaluate the significant relation of these five factors to in-hospital COVID-19 mortalities. We conducted a retrospective, cross-sectional, and observational cohort study between Jan 01 and May 30, 2021 in a tertiary care center in India. The outcome of interest is to identify the effect of vaccination, co-morbidities, and Remdesivir administration on COVID-19 mortality using SPSS software version 25.0 (IBM Corp., Armonk, NY, USA). The mortality rate was found to be 6.8 % (N=117) during hospitalization. The mean age of patients who died due to COVID-19 was 70.41 ± 15.04 years and the median was 68.34 (IQR: 59.61-83.38) years. About 89% of the population was over 55 years of age. The mortality rate was found to be higher in males (N=77; 65.8%). Out of 117 deaths, 95 patients (81.2%) were unvaccinated, whereas only 15.4% (N=18) and 3.4% (N=4) have taken a single and double dose respectively. Approximately, 3 quarter of patients had 1 or more comorbidity. Remdesivir administration is associated with the survival of 84.0% in moderate to severe COVID-19 infected patients. Results of our study coincide with the outcomes of studies done in the past concluding that age, gender, pre-existing comorbidities, vaccination status, and Remdesivir administration, these five factors are associated with COVID-19 mortalities.